ÂÜÀòÂÒÂ×

Alan Joslyn is a seasoned executive in the biotechnology and pharmaceutical sectors, currently serving as a Partner at Lazarus Pharmaceuticals since April 2014, focusing on gastroenterology asset financing and due diligence. Joslyn has held significant leadership roles, including Chief Executive Officer of Inimmune from May 2022 to November 2024, where achievements included a worldwide deal for vaccine adjuvants and establishing an Australian subsidiary for clinical trials. Previously, Joslyn served as CEO of Oragenics, Inc., overseeing initiatives in infectious diseases and Covid-19 vaccine development, and held CEO positions at Sentinella Pharmaceuticals and Edusa Pharmaceuticals. Joslyn holds a Ph.D. in Pharmacology and a Doctor of Philosophy in Biochemical Pharmacology from the University at Buffalo, completed in 1986.